ALOX5 and nonpapillary renal cell carcinoma: To determine whether 5-LOX pathway activity was required for ferroptosis sensitivity in ccRCC cells, we tested whether the FDA approved 5-LOX inhibitor, zileuton, could block erastin-induced ferroptosis.